Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Immune-mediated adverse events"'
Autor:
A. A. Glibka, N. V. Mazurina, E. A. Troshina, K. A. Sarantseva, G. Yu. Kharkevich, M. V. Volkonskii, A. R. Elfimova
Publikováno v:
Ожирение и метаболизм, Vol 21, Iss 1, Pp 42-57 (2024)
BACKGROUND: Overweight and obesity have a significant impact on the course and results of treatment of many diseases, including cancer. One of the modern types of antitumor therapy is immune checkpoint inhibitors. Taking into account the high effecti
Externí odkaz:
https://doaj.org/article/7e0ebbaa233b4fd4bd6bf97d481edf63
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundWe conducted an overview to assess immune adverse effects associated with the COVID-19 vaccine, guiding safer choices and providing evidence-based information to clinicians.MethodsForty-three studies on adverse effects of vaccines were revi
Externí odkaz:
https://doaj.org/article/96de4e9e775d47c4b788ee84dd198386
Publikováno v:
Gynecologic Oncology Reports, Vol 53, Iss , Pp 101382- (2024)
Externí odkaz:
https://doaj.org/article/6d976c6003554c32b9f9f52184ca702d
Autor:
A. D. Koltakova, A. M. Lila
Publikováno v:
Современная ревматология, Vol 17, Iss 5, Pp 112-117 (2023)
Checkpoint inhibitors (CPI) are anticancer drugs that activate the immune response against cancer cells. This type of treatment is highly effective, but also associates with many immunoinflammatory complications, including musculoskeletal. This revie
Externí odkaz:
https://doaj.org/article/5ae41e73226e4f3b90395de2644129fc
Publikováno v:
Современная онкология, Vol 25, Iss 1, Pp 140-144 (2023)
Nowadays, checkpoint inhibitors are widely used in the treatment of various types of cancer. However, its use is often accompanied by the development of immune-mediated adverse events (IAEs) of various systems and organs. Aim description of the featu
Externí odkaz:
https://doaj.org/article/af0a959144bd413f84539f1a1b65aa79
Autor:
Anastasia A. Glibka, Natalya V. Mazurina, Danila I. Gridnev, Ksenia A. Sarantseva, Ekaterina A. Troshina
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 50, Iss 8, Pp 490-496 (2023)
Active implementation of immune checkpoint inhibitors into oncology practice leads to an increase in numbers of observed immune-mediated adverse events, including various endocrinopathies. The focus is on multiple endocrine gland involvement because
Externí odkaz:
https://doaj.org/article/70ce2495711b4a6fb0b093cdde35e270
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A. D. Koltakova, A. M. Lila, O. G. Alekseeva, A. A. Fedenko, Y. V. Gridneva, A. S. Olshanskaya
Publikováno v:
Современная ревматология, Vol 16, Iss 5, Pp 46-52 (2022)
Objective: to describe musculoskeletal immune-mediated adverse events (iAEs) associated with the therapy of solid tumors with immune checkpoint inhibitors (ICIs, inhibitors of the PD-1/PD-L1 pathway).Patients and methods. 13 patients receiving ICIs t
Externí odkaz:
https://doaj.org/article/b651571d2d7d46de90e558bff186e959
Autor:
Marina A. Lyadova, Vladimir K. Lyadov
Publikováno v:
Современная онкология, Vol 23, Iss 2, Pp 319-326 (2021)
Immune-mediated adverse events (imAEs) are complications of therapy with immune checkpoint inhibitors, which arise as a result of autoimmune inflammation. The article summarizes systemic (fatigue, fever), cutaneous (rash, itching), gastrointestinal (
Externí odkaz:
https://doaj.org/article/3a154e511d494ed0b9aa3f44adddd121
Autor:
M. A. Lyadova, V. K. Lyadov
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 26-32 (2021)
In the recent years the growing life expectancy of the population and increasing cancer burden in elderly patients substantiate the urgent need for the search of optimal cancer treatment strategies. This article provides an overview of the current li
Externí odkaz:
https://doaj.org/article/40381f36fa8b46a5bbac5ce2ed2b4a30